FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
1/22/2025 9:59:02 PM | Chg. -0.310 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
35.720EUR | -0.86% | 9,970 Turnover: 359,943.500 |
-Bid Size: - | -Ask Size: - | 20.14 bill.EUR | - | - |
GlobeNewswire
4/24/2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
4/23/2024
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2/23/2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
9/4/2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
8/31/2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil